21-12-2017
Hailshadow / iStockphoto.com
Médecins Sans Frontières (MSF) has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Médecins Sans Frontières, MSF, Gilead, hepatitis C, I-MAK, Sovaldi, sofosbuvir, SIPO, State Intellectual Property Office
MSF critical of EPO decision to uphold Gilead’s hepatitis C patent
17-09-2018
MSF challenges Gilead patent in China
20-06-2018
Non-profit asks US government to take Gilead hepatitis C patent
20-03-2018
Gilead gets Sovaldi patent approval in India despite opposition
10-05-2016
MSF urges Indian Patent Office to reject Gilead Sovaldi patent
02-03-2016
